Search clinical trials for: BIBR 1048 capsule

Total 4116 results

Boehringer Ingelheim

Completed

Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy Males

Healthy
Boehringer Ingelheim

Completed

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Boehringer Ingelheim

Completed

Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects

Healthy
Beijing Union Pharmaceutical Factory Ltd
R&G Pharma Studies Co.,Ltd.

Recruiting

Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD (BGFN-2022-02)

Generalized Anxiety Disorder

China
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Prostatic Neoplasms

United Kingdom
Shanghai Jiao Tong University School of Medicine
Shanghai Chest Hospital

Recruiting

Limonene for Pulmonary Nodule Chemoprevention

Pulmonary Nodules

China
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers

Healthy
Shire

Completed

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

Healthy
Saisei Pharma

Completed

Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR)

Covid19

Ukraine
Boehringer Ingelheim

Completed

BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Reata, a wholly owned subsidiary of Biogen

Completed

RTA 408 Capsules in Patients With Melanoma - REVEAL

Melanoma | Unresectable (Stage III) Melanoma | Metastatic (Stage IV) Melanoma

United States
Boehringer Ingelheim

Completed

Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers

Healthy
Reata, a wholly owned subsidiary of Biogen

Completed

Safety and PK/PD of RTA 1701 in Healthy Adults

Healthy

Australia
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

Healthy
Hongsheng Tan
Shanghai Shen Kang Hospital Development Center; Longhua Hospital; Hongqiao International...

Completed

Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution (DL-MAFLD-TCM)

Fatty Liver

China
Boehringer Ingelheim

Terminated

Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease

Crohn Disease
Boehringer Ingelheim

Completed

BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery

Venous Thromboembolism

Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Italy, Netherlands, Norway, South Africa, Sweden
Forest Laboratories

Completed

PR-018: An Open-Label, Safety Extension of Study PR-011

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Enzychem Lifesciences Corporation

Completed

EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

Stomatitis

United States
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy Subjects

Healthy
OPKO Health, Inc.

Completed

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism | Vitamin D Insufficiency

United States
Boehringer Ingelheim

Completed

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Neoplasms

France
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Healthy
First Affiliated Hospital Xi'an Jiaotong University

Unknown

A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie Capsule

Fibrocystic Disease of Breast

China
Boehringer Ingelheim

Completed

Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects

Healthy
Natrogen Therapeutics International, Inc

Unknown

Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis

Ulcerative Colitis

United States
Boehringer Ingelheim

Completed

BIBR 953 ZW in Healthy Elderly Subjects

Healthy
Boehringer Ingelheim

Completed

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Neoplasms

United States
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
University of Texas Southwestern Medical Center
Stanley Medical Research Institute; ACADIA Pharmaceuticals Inc.

Completed

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics (ACP-104)

Schizophrenia

United States

3

Subscribe